ULB Belgium’s ethical commitee has approved the protocol for an open phase II study of standard treatments in combination with Gliovac/ERC1671/SITOIGANAP vs standard treatments without Gliovac/ERC1671/SITOIGANAP in the treatment of Glioblastoma multiforme. For further information go to the publications page.
